Vivani Medical Inc. (VANI), a specialized medical technology firm, stands as a testament to the dynamic fusion between innovative tech and healthcare. The company is dedicated to revolutionizing the medical sector by advancing key medical imaging technologies that enhance the accuracy, safety, and efficiency of various diagnostic and therapeutic procedures.
VANI has made a name for itself in the field of medical tech through its unparalleled commitment to the development, commercialization, and distribution of cutting-edge medical imaging technologies. The company's prime focus is to provide healthcare professionals with unprecedented visualization capabilities, enabling them to make timely, informed, and precise decisions.
At the core of Vivani Medical Inc.'s offerings is a broad range of advanced imaging technologies known for their exceptional quality, performance, and reliability. These include multi-modular imaging systems, AI-powered diagnostic tools, and high-resolution imaging equipment. Leveraging top-tier engineering and innovation, Vivani Medical Inc. ensures these technologies cater to various health sector needs, such as diagnostic imaging, surgical guidance, therapeutic procedures, cancer screening, and more.
VANI's team of experts and industry professionals spearhead the development and manufacturing processes with an unwavering commitment to quality. The company’s robust quality management and regulatory compliance system speak volumes about its dedication to upholding the highest standards. The R&D teams work passionately to engineer optimized solutions that not only meet the ever-evolving needs of the medical industry but also set new benchmarks in innovation.
VANI's approach is customer-centric, aiming to enhance patient outcomes through its advanced product portfolio. Its commitment to empowering health professionals with state-of-the-art imaging technologies significantly optimizes patient diagnostics, improving overall healthcare delivery.
Alongside its principal operations, Vivani Medical Inc. also believes in the power of collaboration, taking pride in establishing partnerships with leading medical institutions and technology developers. These collaborations facilitate the continuous improvement and advancement of its imaging technologies, ultimately fulfilling VANI's mission to revolutionize the medical sector through technology.
In conclusion, Vivani Medical Inc. operates at the forefront of the medical tech industry as a trusted provider of imaging solutions. Whether through their industry-leading technologies or customer-centric ethos, VANI is undeniably making waves in the market and potentially paving the way to redefine future healthcare.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Vivani Medical, Inc. (NASDAQ:VANI) announced that the expected October 2026 completion of its Cortigent-ClearOne merger has been postponed. The delay is due to pending final regulatory clearance for the deal, which involves Cortigent, a wholly-owned subsidiary of Vivani Medical, merging into CLRO Merger Sub, Inc. and becoming a wholly-owned subsidiary of ClearOne, Inc. The parties anticipate the closing will take place shortly after receiving this approval.
Vivani Medical (NASDAQ:VANI) shares experienced a 9.1% drop, trading down to $1.355 with significantly higher trading volume. Analyst sentiment is mixed, with an average "Hold" rating but individual "Buy" ratings from some firms, and insider ownership remains substantial at 53.3%. The company's recent earnings beat estimates, reporting a quarterly loss of $0.07 per share against an estimated $0.08 loss.
Vivani Medical has released an investor deck detailing its NanoPortal ultra-long-acting subdermal GLP-1 implant platform, aiming for once- or twice-yearly dosing for chronic weight management. Their lead candidate, NPM-139 (a semaglutide implant), is in the SLIM-1 study with top-line data expected in November 2026, and a Phase 2 study is planned for 2027. The company's cash runway is projected to last through the first half of 2027, covering key milestones, while noting the significant 2025 global sales of FDA-approved GLP-1 products and their high discontinuation rates.
Wall Street Zen has upgraded Vivani Medical (NASDAQ:VANI) from a "sell" to a "hold" rating, contributing to a consensus "Hold" rating with an average price target of $3.75. Analyst opinions are varied, with Lake Street Capital initiating coverage with a "buy" rating and a $4.00 target. Vivani Medical shares opened at $1.40, and the company recently reported a quarterly loss of $0.07 per share, beating estimates by $0.01, with a significant insider purchase by director Gregg Williams.